Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005
Linda M. Griffith(National Institute of Allergy and Infectious Diseases), Richard A. Nash(Colorado Blood Cancer Institute), Maureen D. Mayes(The University of Texas Health Science Center), Stephen J. Forman(City Of Hope National Medical Center), Jacob M. van Laar(University Medical Center Utrecht), James D. Bowen(Swedish Medical Center), Roland Martinꝉ(University of Zurich), Riccardo Saccardi(Azienda Ospedaliero-Universitaria Careggi), Steven Z. Pavletic(National Institutes of Health), Aloïs Gratwohl, Brenda M. Sandmaier(University of Washington), Alan Tyndall(University of Basel), Peter A. McSweeney(Mesoblast (United States)), Harry Openshaw(City Of Hope National Medical Center), Christopher Bredeson, Richard Childs(National Heart Lung and Blood Institute), Paolo A. Muraro(Imperial College Healthcare NHS Trust)
Cited by 57
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k